Quote:

---

WE will likely be used as a adjuvant therapy...because that is where LL is capable...supporting others that have Black box warnings and looming Patent cliffs.

---

We will initially be stuck there because the FDA likes to pair a new drug in trials with an already existing proven drug so the patient has treatment even if the new drug doesn't work. The exception will be Alzheimer's because there is no real effective treatment.

The results from the Alzheimer's pilot study is what I'm really looking forward too. Hopefully whomever is doing the study has a decent number of patients and excludes for the CCR5 Delta 32 double allele deletion. The results from that study should really open some eyes and a successful phase 2 trial for Alzheimer's would have a decent chance of getting a conditional approval.